SCHEMBL30403752

SCHEMBL30403752

COc1ccc2c(c1)CCCN2CCN(C)C

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 1/20 0.50
KDM4E B2RXH2 1/20 0.50
ALDH1A1 P00352 1/20 0.50
LMNA P02545 1/20 0.50
MAPT P10636 1/20 0.50
PTK2B Q14289 1/20 0.50
ESR2 Q92731 1/20 0.50
NOS3 P29474 3/20 0.48
NOS1 P29475 3/20 0.48
HDAC1 Q13547 1/20 0.48
HDAC6 Q9UBN7 1/20 0.48
HRH3 Q9Y5N1 1/20 0.47
DRD1 P21728 6/20 0.46
DRD2 P14416 5/20 0.46
DRD5 P21918 5/20 0.46
DRD3 P35462 5/20 0.46
DRD4 P21917 4/20 0.46
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
NOS2 P35228 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24110550 1.00 HSD17B10 (0.50) HSD17B10KDM4EALDH1A1LMNAMAPT
SCHEMBL24109783 0.92 KDM4E (0.60) HSD17B10KDM4EALDH1A1LMNAMAPT
SCHEMBL10815104 0.85 KMT2A (0.57) HSD17B10KDM4EALDH1A1LMNAMAPT
SCHEMBL25818515 0.82 ALDH1A1 (0.54) HSD17B10KDM4EALDH1A1LMNAMAPT
SCHEMBL12061308 0.81 HRH3 (0.62) HSD17B10ALDH1A1HDAC1HDAC6HRH3
SCHEMBL2675622 0.81 NOS3 (0.53) HSD17B10KDM4EALDH1A1LMNAMAPT
SCHEMBL24110325 0.79 HDAC1 (0.52) HSD17B10HDAC1HDAC6HRH3DRD1
SCHEMBL19871391 0.78 HSD17B10 (0.47) HSD17B10HDAC1HDAC6HRH3DRD1
SCHEMBL1450332 0.77 ALDH1A1 (0.82) KDM4EALDH1A1LMNAMAPTPTK2B
SCHEMBL10816704 0.77 HSD17B10 (0.51) HSD17B10HDAC1HDAC6HRH3DRD1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4165049-A1 ISOTRYPTAMINE PSYCHOPLASTOGENS AND USES THEREOF Delix Therapeutics, Inc. (US) 2023-04-19 EP disclosed